Henry Schein, Inc. (HSIC)

FairStock Score: 46/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn high returns on capital and trade at a discount to intrinsic value. Henry Schein is a durable distributor of dental and medical products, but the numbers show a mediocre economic engine. At the close on 2026-10-26, the price was $84.51 and market cap $9.4B. FairStock's calculations show a P/E of 24.64, P/B of 3.00, ROE of 8.85%, ROCE of 4.39%, and a Graham Number of $46.66, leaving a negative margin of safety of 82.08%. FCF was $513.0M TTM, a 5.4% FCF yield; that is respectable but not enough to offset the valuation. Filed results show in fiscal year 2025 ended 2025-12-27 revenue of $13.2B, net income of $398.0M, and diluted EPS of $3.27, versus fiscal year 2024 ended 2024-12-28 revenue of $12.7B, net income of $390.0M, and diluted EPS of $3.05. The latest quarter, fiscal Q2 2026 ended 2026-06-27, had revenue of $3.5B, net income of $94.0M, and diluted EPS of $0.82, compared with fiscal Q2 2025 ended 2025-06-28 revenue of $3.2B, net income of $86.0M, and diluted EPS of $0.70. Growth is modest. FairStock classifies it as a SLOW GROWER — Shrinking: profit -0.3% a year over five years, revenue 5.4%. The balance sheet is not alarming, but D/E of 0.81 and Altman Z-Score of 1.73 warrant caution. Piotroski 6/9, PEG 2.66, and a 46/100 FairStock Score suggest average quality at a full price. I see a decent business, no bargain.

In plain English: Henry Schein sells supplies and services to dental and medical practices. The business is steady but not very profitable, and it has grown slowly. At the recent stock price, the shares look expensive compared with the company's profits and the value of its assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-27) · fiscal Q1 2026 10-Q (period ended 2026-03-28) · fiscal Q3 2025 10-Q (period ended 2025-09-27) · fiscal Q2 2025 10-Q (period ended 2025-06-28) · FY2025 10-K (period ended 2025-12-27) · FY2024 10-K (period ended 2024-12-28) · FY2023 10-K (period ended 2023-12-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer